相关实验视频

Updated: May 8, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

基因组测试在前列腺癌护理中的整合:对临床实践和患者结果的影响

Christos Roidos¹, Anastasios Anastasiadis¹, Stavros Tsiakaras¹

¹First Department of Urology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece.

Current issues in molecular biology

|December 27, 2024

概括

像Prolaris,Oncotype DX和 Decipher这样的基因组测试有助于前列腺癌 (PCa) 的预后和治疗决策. 虽然有些人与结果有很强的相关性,但为了广泛的临床使用,需要进一步验证.

科学领域:

泌尿器科泌尿器科泌尿器科泌尿器科
在瘤学瘤学.
基因组学就是基因组学.

背景情况:

前列腺癌 (PCa) 是全球癌症相关死亡的重要原因.
基因组测试越来越多地用于评估PCa的攻击性和指导治疗,特别是在低风险和中等风险病例中.

研究的目的:

审查关于四种基因组测试 (Prolaris,Promark,Oncotype DX,Decipher) 的文献,用于PCa预后和治疗决策.
为了比较这些测试在预测诸如复发,转移和死亡率等结果中的实用性.

主要方法:

对评估前列腺癌中的Prolaris,Promark,Oncotype DX和 Decipher研究的文献综述.
基因组测试结果与生物化学复发,转移和前列腺癌特异性死亡率 (PCSM) 等临床结果之间的相关性分析.

主要成果:

普罗拉里斯与复发,转移风险,PCSM和病理特征有很强的相关性.
瘤型DX显示了高分数和死亡率之间的明显联系;解读结果有争议,但与治疗决定有关.
对比分析表明PCSM的型DX,转移的解密和复发预测的Prolaris.

结论:

基因组测试是PCa精准医学的有希望的辅助工具,改善风险分层和个性化治疗,特别是对于中等风险患者.
需要大规模的前性研究来验证这些基因组测试在常规临床整合之前.

关键词:

解读它是为了解读它.瘤类型Dxx 在这就是Prolaris Prolaris.在Promark中使用Promark.生物标志物生物标志物死亡率死亡率预后预后预后前列腺癌是前列腺癌.风险分层的分层化

更多相关视频

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Issues And Trends In Healthcare Delivery System

Issues And Trends In Healthcare Delivery System

The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...